Ronald Stout
National Health Service
30 Papers
565 Citations
Ronald Stout is an academic researcher from National Health Service. The author has contributed to research in topics: Lung cancer & Ifosfamide. The author has an hindex of 18, co-authored 30 publications.
Chat about Author
Papers
Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial
Anna Gregor,Ann Cull,Richard Stephens,J A Kirkpatrick,John Yarnold,David J. Girling,Fergus Macbeth,Ronald Stout,D. Machin +8 more
TL;DR: Prophylactic cranial irradiation (PCI) reduces the risk of cranial metastasis in small cell lung cancer (SCLC), but the magnitude and value of this reduction, the risks of radiation morbidity and whether PCI influences survival are unclear as discussed by the authors.
362
Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery.
TL;DR: Survival following well planned radiotherapy is an effective alternative to surgery for both squamous cell and adenocarcinoma and the use of multimodality treatment may further improve survival.
104
Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer.
Ronald Stout,Philip Barber,Paul A Burt,Penelope Hopwood,Ric Swindell,Jackie Hodgetts,Lyn Lomax +6 more
TL;DR: Fractionated XRT is preferred to EBT as an initial treatment in better performance patients because it provides better overall and more sustained palliation with fewer retreatments and a modest gain in survival time.
103
Neurological and Cognitive Impairment in Long-term Survivors of Small Cell Lung Cancer
Ann Cull,A. Gregor,Penelope Hopwood,Fergus Macbeth,H. Karnicka-Mlodkowska,Nick Thatcher,Paul A Burt,Ronald Stout,Kasia Stepniewska,M. Stewart +9 more
TL;DR: The role of prophylactic cranial irradiation (PCI) in the management of small cell lung cancer (SCLC) remains controversial because of concern about radiation-induced neurological morbidity as discussed by the authors.
91
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma
Sarah Danson,Mark R. Middleton,Kenneth J. O'Byrne,Mark Clemons,Malcolm R Ranson,Jurjees Hassan,Heather Anderson,Paul A Burt,Corrine Fairve-Finn,Ronald Stout,Isabel Dowd,Linda Ashcroft,Cheryl Beresford,Nick Thatcher +13 more
- 01 Jan 2003
TL;DR: In this article, the authors compared gemcitabine and carboplatin (GC) with mitomycin, ifosfamide, and cisplatin (MIC) in patients with advanced nonsmall cell lung carcinoma.
75